OrbiMed
Investor profile
OrbiMed has backed 13 European tech companies across 14 funding rounds between 2015 and 2025, joining rounds totalling €1.1B. Most active in Healthtech and AI. Data as of 4 Nov 2026.
Deals
14
distinct rounds
Companies
13
backed
Active span
2015–2025
11 yrs
Total round €
€1.1B
sum of rounds joined
Deals by year
distinct rounds / yearOrbiMed — deals by year — interactive chart.
Data table
| OrbiMed — deals by year | |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 3 |
Top sectors
by dealsOrbiMed — top sectors — interactive chart.
Data table
| OrbiMed — top sectors | |
|---|---|
| Healthtech | 12 |
| AI | 2 |
| Energy | 1 |
| Fintech | 1 |
Stages
by dealsOrbiMed — stages — interactive chart.
Data table
| OrbiMed — stages | |
|---|---|
| Series B | 4 |
| Series C | 4 |
| Series A | 3 |
| Other | 2 |
| Seed | 1 |
Countries
by dealsOrbiMed — countries — interactive chart.
Data table
| OrbiMed — countries | |
|---|---|
| Israel | 4 |
| UK | 3 |
| Denmark | 2 |
| Switzerland | 2 |
| France | 1 |
| Germany | 1 |
| Ireland | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Novo Holdings3
- EQT Life Sciences2
- F-Prime Capital2
- Khosla Ventures2
- Seventure Partners2
- Sofinnova Partners2
- Adjuvant Capital1
- Andera Partners1
- ATEM1
- Atlantic Bridge1
- Aurum Ventures1
- Axial1
- Braavos Capital1
- Bristol Myers Squibb1
- Cowen Healthcare Investments1
- Crédit Agricole Création1
- CTI Life Sciences1
- Driehaus Capital Management1
- Enterprise Ireland1
- Eventide Asset Management1
- Forbion1
- Forbion's Growth Opportunities Fund1
- Frazier Life Sciences1
- Ganot Capital1
- General Atlantic1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Verdiva Bio | UK | 1 | €399M |
| Amolyt Pharma | France | 1 | €129M |
| Vectivbio | Switzerland | 1 | €127M |
| Charm Therapeutics | UK | 2 | €116M |
| Galecto Biotech | Denmark | 1 | €79M |
| ProVerum | Ireland | 1 | €68M |
| ObsEva | Switzerland | 1 | €54M |
| MinervaX | Denmark | 1 | €54M |
| BiomX | Israel | 1 | €22M |
| Azura Ophthalmics | Israel | 1 | €17M |
| blue inductive | Germany | 1 | €6.0M |
| MobileODT | Israel | 1 | €3.4M |
| Nucleix | Israel | 1 | €2.7M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Verdiva Bio | Series A | €399M | 2025-01 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Vectivbio | Other | €127M | 2022-10 |
| Galecto Biotech | Series C | €79M | 2018-10 |
| Charm Therapeutics | Series B | €69M | 2025-09 |
| ProVerum | Series B | €68M | 2025-08 |
| ObsEva | Series B | €54M | 2015-11 |
| MinervaX | Other | €54M | 2023-10 |
| Charm Therapeutics | Series A | €47M | 2022-06 |
| BiomX | Series A | €22M | 2017-05 |